MDNAF — Medicenna Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Medicenna Announces Nasdaq Delisting And Cutback Of Management Team
Brief: Medicenna Therapeutics Appoints Humphrey Gardner As Chief Medical Officer
Brief: Medicenna Announces The Appointment Of Jeff Caravella As Chief Financial Officer
Brief: Medicenna Therapeutics Completes MDNA11 Dose Escalation And Commences Monotherapy Dose Expansion In Phase 1/2 Ability Study
Brief: Medicenna Strengthens Ip Portfolio With U.S. Patent Granted For The Use Of Interleukin-2 Superkine Fusion Proteins In Oncology
Brief: Medicenna Granted 180-Day Extension To Meet Nasdaq Minimum Bid Price Requirement
Brief: Medicenna Provides Clinical Update From Monotherapy Dose Escalation Portion Of Phase 1/2 ABILITY Study
Brief: Medicenna Establishes At-The-Market Sales Facility
Brief: Medicenna Reports Q3 2023 Financial Results And Operational Highlights
Brief: Medicenna Strengthens IP Protection For MDNA11, BiSKITS Programs
Brief: Medicenna Reports Second Quarter Fiscal 2023 Financial Results
Brief: Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Medicenna Therapeutics Received Conditional Approval To Extend Expiry Date Of Warrants
Brief: Medicenna Reports Confirmed Partial Response In Pancreatic Cancer And Clinical Update On Mdna11’S Monotherapy Dose Escalation Portion Of The Ongoing Phase 1/2 Ability Study
Brief: Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity Of Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist
Brief: Medicenna Announces Clinical Collaboration With Merck To Evaluate MDNA11 In Combination With Keytruda® (Pembrolizumab) In Ability Trial
Canada Research Roundup: Bank of Montreal, National Bank of Canada, Toronto-Dominion Bank
Brief: Medicenna Reports Q1 Fiscal 2023 Financial Results
Brief: Medicenna Announces Pricing Of $20 Mln Public Offering Of Units